For STAG2, the predicted mutational burden in normal tissue matched that in CRC within a lifetime (69 years; range 13–110 years) (Fig. 2H), indicating that the frequency of inactivating STAG2 mutations in CRC can be almost entirely attributed to positive selection in normal tissue. The gene discussed is STAG2; the disease is colorectal carcinoma.